• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Diatide nets milestone for AcuTect

Article

Peptide-based imaging agent developer Diatide has announced that it has received an approvable letter from the Food and Drug Administration for its AcuTect technetium-labeled agent for the imaging of acute venous thrombosis in the lower extremities. The

Peptide-based imaging agent developer Diatide has announced that it has received an approvable letter from the Food and Drug Administration for its AcuTect technetium-labeled agent for the imaging of acute venous thrombosis in the lower extremities. The letter arrived exactly six months following the submission of the new drug application (NDA) to the FDA (SCAN 9/3/97).

The letter indicates that Diatide's NDA will be approved once the company clarifies certain details and formally agrees to specific postapproval requirements, according to the Londonderry, NH-based firm. Diatide expects to begin to co-market AcuTect in the U.S. with its corporate partner Nycomed Amersham immediately following approval of the agent.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.